A year ago, the US Food and Drug Administration (FDA) launched a new “ultra-fast” review programme intended to dramatically shorten review times for drug and biological product applications, as well as for manufacturing or efficacy supplements. The initiative aligns with the agency’s broader effort to improve approval efficiency and modernise regulatory frameworks to address emerging public health needs. With several actions already taken since launch, the FDA plans to publicly review the programme in early June.